Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model.J Control Release. 2003 Dec 12;93(3):377-87.Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Israel. AbstractCannabidiol (CBD) is a new drug candidate for treatment of rheumatic diseases. However, its oral administration is associated with a number of drawbacks. The objective of this study was to design a transdermal delivery system for CBD by using ethosomal carriers. CBD ethosomes were characterized by transmission electron microscopy, confocal laser scanning microscopy and differential scanning calorimetry. Results indicated that CBD and phosphatidylcholine form an eutectic mixture. In vivo application of ethosomal CBD to CDI nude mice produced a significant accumulation of the drug in the skin and in the underlying muscle. Upon transdermal application of the ethosomal system to the abdomen of ICR mice for 72 h, steady-state levels were reached at about 24 h and lasted at least until the end of the experiment, at 72 h. Furthermore, transdermal application of ethosomal CBD prevented the inflammation and edema induced by sub-plantar injection of carrageenan in the same animal model. In conclusion, ethosomes enable CBD's skin permeation and its accumulation in a depot at levels that demonstrate the potential of transdermal CBD to be used as an anti-inflammatory treatment. PMID: 14644587 [PubMed - indexed for MEDLINE] Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Rukwied R, Watkinson A, McGlone F, Dvorak M. Journal - Pain 2003;102(3):283-8. Major outcome(s):A TOPICALly applied cannabinoid receptor agonist (HU210) reduced pain caused by capsaicin ABSTRACT - The induction of hyperalgesia upon capsaicin administration requires activation of specific sub-classes of nociceptive afferent C-fibres providing nociceptive input to the central nervous system.It has been demonstrated in animal models that the endocannabinoid anandamide has anti-hyperalgesic properties upon capsaicin stimulation, albeit it also binds to vanilloid receptors. In the present study we topically administered the cannabinoid receptor ligand HU210 to human skin and investigated its effects on capsaicin-induced pain and hyperalgesia.We demonstrated that pre-treatment with HU210 significantly reduced the perception of pain following the administration of capsaicin. Heat pain thresholds were significantly reduced by capsaicin application measured 5 and 30min after administration. In contrast, at the HU210 pre-treated skin sites capsaicin failed to induce heat hyperalgesia during the fifth minute of administration. Secondary mechanical hyperalgesia to touch (allodynia) was measured during the fifth, 15th and 30th minute after capsaicin administration. In comparison to the ethanol control site, the area of touch-evoked allodynia was significantly reduced at the HU210 skin site during the first two measures. However, 30min after the administration of capsaicin no significant differences of allodynia were observed between the HU210 and ethanol pre-treated skin.The present study provided evidence for analgesic and anti-hyperalgesic properties of a topically applied cannabinoid receptor ligand, which might have important therapeutic implications in humans. Adjuvant TOPICAL therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. Author(s)Phan NQ, Siepmann D, Gralow I, Ständer S. Journal - Competence Center for the Diagnosis and Treatment of Pruritus, Clinic and Polyclinic for Skin Diseases, University Hospital of Münster, Germany. Major outcome(s)Five of eight patients experienced a good pain relief Background: Postherpetic neuralgia is a frequent adverse event in herpes zoster patients and difficult to treat. Conventional analgetic therapy often fails to reduce the burning pain transmitted by unmyelinated nerve fibers. These nerves express cannabinoid receptors which exert a role in modulation of nociceptive symptoms. Therefore, TOPICAL therapy with cannabinoid receptor agonist seems likely to suppress local burning pain. Patients and methods: In an open-labeled trial, 8 patients with facial postherpetic neuralgia received a cream containing the cannabinoid receptor agonist N-palmitoylethanolamine. The course of symptoms was scored with the visual analog scale. Results: 5 of 8 patients (62.5 %) experienced a mean pain reduction of 87.8 %. Therapy was tolerated by all patients. No unpleasant sensations or adverse events occurred. Conclusions: TOPICAL cannabinoid receptor agonists are an effective and well-tolerated adjuvant therapy option in postherpetic neuralgia. [TOPICAL cannabinoid agonists : An effective new possibility for treating chronic pruritus.] [Article in German] Author(s)Stander S, Reinhardt HW, Luger TA. Journa: Hautarzt. 2006 Jul 28; [Epub ahead of print] Major outcome(s)TOPICAL application of a cream with N-palmitoyl ethanolamine [a cannabinoid agonist] had a good antipruritic effect in most patients. Our Research
Our Research ProgramDoc Green's Healing Collective is committed to developing and researching topical cannabis applications for:
|
Here is a valuable database of clinical research and case reports maintained by the International Association for Cannabis. |